Madrigal Pharmaceuticals has reported its Q1 2026 earnings, with some outlets indicating the company beat earnings expectations, while others suggest a narrower-than-expected loss. The reports are inconsistent regarding the company's revenue, with some mentioning sales of a drug driving the top line, but others stating that no revenue was reported. The earnings report appears to have had a varied impact on the company's stock, with some outlets reporting an increase and others a decrease.